We are pleased to announce that glyXera, together with our research partners at the University of Porto, published a new research article in the journal Biochimica et Biophysica Acta (BBA) – General Subjects.
The publication, titled “Targeting cancer cell sialylation with monosaccharide analogues modulates EGFR in colorectal cancer cells”, describes the treatment of colorectal cancer cells with a cell-permeable fluorinated sialic acid analogue. Colorectal cancer is among the most frequently diagnosed malignancies and one of the leading causes of cancer-related deaths worldwide. Aberrant sialylation, particularly increased levels of sialic acid (Neu5Ac), is often recognized as a cancer-associated glycan alteration. Therefore, suppression of hypersialylation is a promising strategy to overcome glycosylation-mediated therapeutic resistance.
The treatment of the colorectal cancer cells led to a competitive inhibition of terminal sialylation. The impact of this treatment on the colorectal cancer cells’ glycosylation was investigated, and the influence on the cells’ malignant properties and responsiveness to EGFR-targeted therapy was elucidated.
The article is published open access and can be read in full on the publication web page: https://www.sciencedirect.com/science/article/pii/S0304416526000553
If you would like to learn more about our high-performance glycan analysis products, including glyXboxCE, or are interested in a research cooperation, please feel free to get in touch.